SIRPA and neoplasm: Currently, several principal therapeutic agents targeting CD47/SIRPα include: (1) Hu5F9-G4 monoclonal antibody, a macrophage checkpoint inhibitor targeting CD47, promotes tumor cell elimination via macrophage-mediated phagocytosis.